Royal Agrifirm Group’s acquisition of Hamlet Protein, completed in May 2026, is viewed as reflective of a certain animal nutrition industry shift in how the world’s largest integrated feed companies approach young animal nutrition, a segment that historically was more associated with the industry’s periphery.
Hamlet Protein, a leader in specialty soy-based protein ingredients for young animal nutrition, has now been integrated into Royal Agrifirm Group’s Specialties division. The company, which will continue operating under its own name, has production facilities in Denmark and the US, along with a sales office in China, and employed approximately 115 people at the time of acquisition.
Erik Visser, CEO of Hamlet Protein, told Expana in a recent interview that Hamlet Protein had operated under private equity ownership since 2015, when Altor Equity Partners and Goldman Sachs acquired the company in equal partnership. This was followed by Altor acquiring Goldman Sachs’ shares in 2024. The original intention of the private equity owners was a buy-and-build approach, yet non-organic growth never materialized for Hamlet Protein. Private equity firms typically own a portfolio company for three to seven years, with around five years being a common target holding period, and this timeline prompted the start of the exit process, Visser said.
When exploring potential suitors, Visser said: “As management we were keen for the next owner of Hamlet Protein to be a strategic buyer with a clear understanding of the markets we operate in.”
The selection of Royal Agrifirm reflected more than financial metrics. “I am very happy we ended up under Royal Agrifirm Group ownership,” Visser commented, adding that both parties identified a cultural match, a complimentary product portfolio, and ample opportunities for growth.
For Visser, Royal Agrifirm’s production locations in China and Brazil will provide Hamlet Protein synergistic opportunities, which can enhance competitiveness, and reduce working capital needs associated with exporting goods from its Danish and US facilities. Combining Hamlet Protein’s and Royal Agrifirm’s research and development (R&D) facilities are also expected to generate cost efficiencies and accelerate initiatives.
“Additional synergies will come from joint procurement, technical insights on optimization of energy use, engineering expertise in production to name just a few,” he added. “Our initial focus is on driving commercial opportunities: cross selling, captive use, integration of distribution network, rather than trying to achieve synergies through cost reduction programs.”
Asked about workforce continuity, Visser stated that the business does not foresee any workforce reduction, emphasizing that Hamlet Protein will continue to operate independently under the Hamlet Protein brand from the existing production and sales platforms, while working closely together with Royal Agrifirm to maximize the realization of potential synergies between both companies.
According to Visser, the acquisition comes at an interesting time for the young animal nutrition sector. He conceded that while the segment has historically proven more resilient than broader animal feed markets, current conditions test that resilience in new ways. “Since the start of 2026, the market has been operating against a backdrop of continued uncertainty in global livestock production, varying regional disease pressures, and ongoing pressure on producer margins. In situations where herd or flock sizes are reduced, demand for young animal nutrition products can inevitably come under pressure because there are simply fewer animals entering the production system,” he said.
Young animal nutrition has long benefited from producer recognition that compromising nutrition during the earliest stages of life carries lasting consequences for growth performance, health, feed efficiency, and overall economics. “In periods of cost pressure, producers often look first at optimizing diets for finishing or mature animals before making significant changes to starter programs,” Visser said.
“In situations where herd or flock sizes are reduced, demand for young animal nutrition products can inevitably come under pressure because there are simply fewer animals entering the production system,” he added. “When livestock populations contract, the sector may see some volume headwinds, but the value proposition of high-quality young animal nutrition remains largely intact.”
Still according to Hamlet Protein’s CEO, today’s young animal nutrition market is considerably more technology-driven than it was a decade ago. Products are increasingly positioned around measurable outcomes such as gut health, survivability, growth rates, and feed conversion. This tends to support demand even in more difficult environments because producers are looking for solutions that improve biological and economic efficiency.
“I would characterize young animal nutrition in 2026 as still relatively resilient compared with broader feed markets, but perhaps somewhat less insulated than in the past. The segment continues to benefit from its critical role in animal performance, yet it is also more exposed to cyclical declines in livestock numbers than many market participants may have assumed during the industry’s strongest growth years,” he summarized.
Over recent years, investment in young animal nutrition has taken multiple forms. Large integrated animal nutrition companies have increased R&D spending on solutions that improve gut health and feed efficiency. Many nutrition companies have expanded their portfolios through acquisitions of specialty ingredients, functional proteins, probiotics, and enzymes… to name a few, targeted at piglets, calves, chicks, and young fish.
Looking ahead, Visser anticipates continued consolidation activity of this nature. “The industry remains fragmented, with numerous specialized technology providers and feed ingredient or feed specialties companies operating alongside large global nutrition groups,” he commented. “Strategic buyers are likely to remain active as they seek differentiated technologies, stronger positions in high-value segments, and broader solution offerings.”
“The acquisition of Hamlet Protein in my view is less likely to be an isolated transaction and more like part of a longer-term consolidation trend in young animal nutrition, where both strategic and financial buyers see opportunities to capture value from improving animal performance at the earliest stages of development,” he argued.
Image source: Hamlet Protein
Written by Simon Duke
